BG66082B1 - Стабилизирани интерферонови състави - Google Patents

Стабилизирани интерферонови състави

Info

Publication number
BG66082B1
BG66082B1 BG107887A BG10788703A BG66082B1 BG 66082 B1 BG66082 B1 BG 66082B1 BG 107887 A BG107887 A BG 107887A BG 10788703 A BG10788703 A BG 10788703A BG 66082 B1 BG66082 B1 BG 66082B1
Authority
BG
Bulgaria
Prior art keywords
ifn
beta
highly purified
mannitol
compositions
Prior art date
Application number
BG107887A
Other languages
English (en)
Other versions
BG107887A (bg
Inventor
Sidney Wolfe
Maninder Hora
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of BG107887A publication Critical patent/BG107887A/bg
Publication of BG66082B1 publication Critical patent/BG66082B1/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретението се отнася до стабилизирани фармацевтични състави, съдържащи INF-бета и високо пречистен манитол. Високо пречистеният манитол стабилизира съставите чрез намаляване образуването на адуктина INF-бета в сравнение със състава на INF-бета, получен с манитол, който не е високо пречистен. Изобретението се отнася и до методи за повишаване стабилността на INF-бета или негов вариант в течен или лиофилизиран състав и за повишаване на стабилността при съхраняването на състава.
BG107887A 2000-11-07 2003-06-06 Стабилизирани интерферонови състави BG66082B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24645600P 2000-11-07 2000-11-07
US25222400P 2000-11-21 2000-11-21
PCT/US2001/047514 WO2002038170A2 (en) 2000-11-07 2001-11-07 Stabilized inteferon compositions

Publications (2)

Publication Number Publication Date
BG107887A BG107887A (bg) 2004-01-30
BG66082B1 true BG66082B1 (bg) 2011-03-31

Family

ID=26937990

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107887A BG66082B1 (bg) 2000-11-07 2003-06-06 Стабилизирани интерферонови състави

Country Status (16)

Country Link
US (2) US6994847B2 (bg)
EP (1) EP1343518B1 (bg)
JP (2) JP4129178B2 (bg)
CN (1) CN1330372C (bg)
AU (2) AU3070702A (bg)
BG (1) BG66082B1 (bg)
CA (1) CA2428144C (bg)
CZ (1) CZ20031259A3 (bg)
DE (1) DE60139339D1 (bg)
ES (1) ES2330508T3 (bg)
HU (1) HU228583B1 (bg)
IL (2) IL155788A0 (bg)
NO (1) NO330690B1 (bg)
PL (1) PL209928B1 (bg)
PT (1) PT1343518E (bg)
WO (1) WO2002038170A2 (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2005011605A2 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
JP5385529B2 (ja) * 2004-04-22 2014-01-08 ハイランド インダストリーズ,インコーポレーテッド スペーサファブリック
US7276275B2 (en) * 2004-04-22 2007-10-02 Highland Industries, Inc. Laminated spacer fabric
CA2607663C (en) 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP5139275B2 (ja) * 2005-06-21 2013-02-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング (r)−(−)−2−[5−(4−フルオロフェニル)−3−ピリジルメチルアミノメチル]クロマンを含有する固体医薬組成物
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CN101190329B (zh) * 2006-11-29 2013-03-06 信谊药厂 一种重组人p43蛋白的药物组合物及其在医药上的应用
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
CN102585011A (zh) * 2012-02-10 2012-07-18 中国农业大学 一种犬α干扰素衍生物的制备方法与应用
KR102534017B1 (ko) 2014-10-23 2023-05-19 암젠 인크 약제학적 제형의 점도 감소
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10799639B2 (en) * 2017-03-03 2020-10-13 Min Wei Syringe type medication delivery device
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439181A (en) 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
DE3273597D1 (en) 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3484374D1 (de) 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
JPS61500439A (ja) 1983-11-21 1986-03-13 リ−ジエンツ オヴ ザ ユニヴア−シテイ− オヴ ミネソタ 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物
US4605555A (en) 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
US4894330A (en) * 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IT1222427B (it) * 1987-07-31 1990-09-05 Sclavo Spa Procedimento per la purificazione di interferone
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
ATE148165T1 (de) 1989-07-24 1997-02-15 Bayer Ag Stabilisierung von hochgereinigten proteinen
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
TW249202B (bg) 1993-08-13 1995-06-11 Ciba Gerigy Corp
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5542303A (en) * 1994-05-12 1996-08-06 Neuffer; A. Erich Dual-peak torque measuring apparatus
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
EP0875253B1 (en) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
ES2330508T3 (es) 2009-12-11
PL366329A1 (en) 2005-01-24
CA2428144A1 (en) 2002-05-16
WO2002038170A2 (en) 2002-05-16
JP2008069171A (ja) 2008-03-27
HU228583B1 (en) 2013-04-29
HUP0301653A2 (en) 2007-02-28
IL155788A (en) 2013-09-30
JP2004536021A (ja) 2004-12-02
US7662369B2 (en) 2010-02-16
JP4129178B2 (ja) 2008-08-06
CN1330372C (zh) 2007-08-08
NO20032033L (no) 2003-07-03
CZ20031259A3 (cs) 2004-01-14
AU3070702A (en) 2002-05-21
WO2002038170A3 (en) 2003-03-27
US20020114782A1 (en) 2002-08-22
EP1343518A2 (en) 2003-09-17
NO330690B1 (no) 2011-06-14
HUP0301653A3 (en) 2009-03-30
IL155788A0 (en) 2003-12-23
EP1343518B1 (en) 2009-07-22
US20060008447A1 (en) 2006-01-12
NO20032033D0 (no) 2003-05-06
BG107887A (bg) 2004-01-30
US6994847B2 (en) 2006-02-07
DE60139339D1 (de) 2009-09-03
CA2428144C (en) 2012-01-10
CN1481252A (zh) 2004-03-10
PT1343518E (pt) 2009-08-03
AU2002230707B2 (en) 2006-08-24
PL209928B1 (pl) 2011-11-30

Similar Documents

Publication Publication Date Title
BG66082B1 (bg) Стабилизирани интерферонови състави
GB9930882D0 (en) GLP-2 formulations
AU4478093A (en) PEG-interferon conjugates
DK0758248T3 (da) Formuleringer til faktor IX
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
PL360254A1 (en) Pharmaceutical compositions
WO2001044272A3 (en) Daptomycin analogs as antibacterial agents
BG106013A (bg) Нови съединения и състави като протеазни инхибитори
IT1304152B1 (it) Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
NO20034492D0 (no) HSA-frie formuleringer av Interferon-<beta>
CA2339765A1 (en) Compounds and compositions for delivering active agents
PL365940A1 (en) Novel pharmaceutical composition for administering n-0923
CA2270964A1 (en) Benzonaphthyridines as bronchial therapeutics
WO2000072820A3 (en) Injectable anesthetic formulation
EP0626170A3 (en) Stabilization of pharmacoligically active compounds in controlled release compositions.
CO5050337A1 (es) Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma
BG103958A (bg) Фармацевтични състави на тизоксанид и нитазоксанид
GR3025797T3 (en) New carboxylic-acid esters of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, the preparation of such esters and their use
AU3739500A (en) Protease resistant flint analogs
CA2373827A1 (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
IT1298442B1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
NZ230625A (en) Pentapeptide with inhibitory effect on dna synthesis in regenerating liver and malignant hepatoma
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
GR1002385B (el) Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.
MD2053B1 (en) Remedy with interferon inducing action